Document is current
Any future updates will be listed below
-
Authors
Portuguese, Andrew J. https://orcid.org/0000-0003-1010-4578
Davis, James A. https://orcid.org/0000-0001-7978-1652
Raza, Shahzad https://orcid.org/0000-0002-2739-2265
Castaneda Puglianini, Omar https://orcid.org/0000-0003-0423-5870
Freeman, Ciara
Alsina, Melissa
Wright, Corbin https://orcid.org/0000-0002-6618-440X
Blue, Brandon J. https://orcid.org/0000-0003-0639-3768
Baz, Rachid C.
Shain, Kenneth H.
Goel, Utkarsh https://orcid.org/0000-0003-1663-0325
Khouri, Jack https://orcid.org/0000-0002-2473-6528
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
Ali, Hossam M. https://orcid.org/0009-0006-3778-5499
Pasvolsky, Oren https://orcid.org/0000-0001-9193-0059
Gaballa, Mahmoud https://orcid.org/0000-0002-3928-6590
Patel, Krina https://orcid.org/0000-0002-8894-027X
Garcia-Pleitez, Hector https://orcid.org/0009-0007-9711-7473
Mikulski, Damian https://orcid.org/0000-0002-2806-2583
Fogel, Lindsay https://orcid.org/0009-0008-3678-2805
Zolotov, Eli
Sannareddy, Aishwarya
Afrough, Aimaz https://orcid.org/0000-0003-2645-8557
Anderson, Larry D. Jr https://orcid.org/0000-0002-6531-9595
Julian, Kelley https://orcid.org/0000-0002-2111-2461
Dima, Danai https://orcid.org/0000-0002-3587-7975
Banerjee, Rahul https://orcid.org/0000-0003-3781-5441
Liang, Emily C.
Cassano Cassano, Raffaella
Herr, Megan M. https://orcid.org/0000-0001-5768-9396
Hassan, Hamza https://orcid.org/0000-0003-1775-2703
Shune, Leyla
Kort, Jeries
Midha, Shonali https://orcid.org/0000-0003-4948-5507
Nadeem, Omar https://orcid.org/0000-0002-4124-4277
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Lin, Yi https://orcid.org/0000-0002-1556-6416
Locke, Frederick L.
Hansen, Doris K. https://orcid.org/0000-0002-9813-3578
Sborov, Douglas https://orcid.org/0000-0003-4268-2698
Biran, Noa https://orcid.org/0000-0003-0693-4202
Grajales-Cruz, Ariel
- License Information
-
More Information
Article History
Received: 4 November 2025
Revised: 6 February 2026
Accepted: 12 March 2026
First Online: 27 March 2026
Competing interests
: AJP reports consulting for Capvision and Karyopharm. SR reports research funding from Janssen Research Developments and Nexcella, and participation on advisory panels for Janssen, Nexcella, Prothena Biosciences, Pfizer, and Kite Pharma. RB reports consulting for AbbVie, Adaptive Biotechnologies, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Poseida Therapeutics, Pfizer, Sanofi, and SparkCures, and research funding from AbbVie, Bristol Myers Squibb, Janssen, Novartis, Pack Health, Prothena, and Sanofi. FA has served as an advisor or speaker for Bristol Myers Squibb, Celgene, Caribou Biosciences, GI Innovation, and Poseida Therapeutics, and has received research funding from Allogene Therapeutics, Celgene, Bristol Myers Squibb, and Caribou Biosciences. FL has served as a consultant or advisor to A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, AstraZeneca, Bluebird Bio, Bristol Myers Squibb, Calibr, Caribou, EcoR1, GLG, Iovance, Kite, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, and Poseida; serves on the NCI CAR T-cell Therapy Safety Oversight DSMB; has received institutional research funding from 2SeventyBio, Allogene, Bristol Myers Squibb, Incyte, Kite, the Leukemia & Lymphoma Society, the Mark Foundation, and the National Cancer Institute; holds institutional patents in cellular immunotherapy; and has participated in educational activities with Aptitude Health, ASH, ASTCT, Clinical Care Options, and the Society for Immunotherapy of Cancer.
